175
Participants
Start Date
December 19, 2022
Primary Completion Date
June 26, 2030
Study Completion Date
June 26, 2030
onasemnogene abeparvovec
Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
RECRUITING
Novartis Investigative Site, Randwick
RECRUITING
Novartis Investigative Site, Leuven
RECRUITING
Novartis Investigative Site, Taipei
RECRUITING
Novartis Investigative Site, Bangkok
RECRUITING
Novartis Investigative Site, Riyadh
RECRUITING
Child Hosp Of The Kings Daughters, Norfolk
RECRUITING
Novartis Investigative Site, Toulouse
RECRUITING
Novartis Investigative Site, Kuala Lumpur
RECRUITING
Novartis Investigative Site, Kuala Lumpur
RECRUITING
Novartis Investigative Site, Strasbourg
RECRUITING
Novartis Investigative Site, Bron
RECRUITING
Novartis Investigative Site, Kaohsiung City
RECRUITING
Novartis Investigative Site, Garches
RECRUITING
Novartis Investigative Site, Hanoi
RECRUITING
Novartis Investigative Site, Beijing
RECRUITING
Novartis Investigative Site, Beijing
RECRUITING
Novartis Investigative Site, Singapore
RECRUITING
Novartis Investigative Site, Chongqing
RECRUITING
Novartis Investigative Site, Guangzhou
RECRUITING
Novartis Investigative Site, Chengdu
RECRUITING
Novartis Investigative Site, Montreal
RECRUITING
Novartis Investigative Site, Copenhagen
RECRUITING
Novartis Investigative Site, Roma
RECRUITING
Novartis Investigative Site, Kurume
RECRUITING
Novartis Investigative Site, Shinjuku Ku
RECRUITING
Novartis Investigative Site, Utrecht
RECRUITING
Novartis Investigative Site, Barcelona
RECRUITING
Novartis Investigative Site, London
RECRUITING
Novartis Investigative Site, Newcastle upon Tyne
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY